1816 energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav. 2010;95:375–82. 80. Pavon FJ, Serrano A, Perez-Valero V, et al. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol. 2008;20:116–23. 81. Sink K, Segovia K, Nunes E, et al. Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats. Psychopharmacology (Berl). 2009;206:223–32. 82. Son MH, Kim HD, Chae YN, et al. Peripherally acting CB1- receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. Int J Obes. 2010;34:547–56. 83. Turu G, Hunyady L. Signal transduction of the CB1 cannabi- noid receptor. J Mol Endocrinol. 2010;44:75–85. 84. Chen RZ, Frassetto A, Lao JZ, et al. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabi- noid CB1 receptor. Eur J Pharmacol. 2008;584:338–42. 85. Receveur JM, Murray A, Linget JM, et al. Conversion of 4- cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier. Bioorg Med Chem Lett. 2010;20:453–7. 86. Fridberg M, Little PB, Cooper M, Jensen NO, Elling CE. A single ascending dose study of TM38837-a novel second generation peripheral selective CB1 receptor antagonist in health male volunteers. Obes Rev. 2010;10(supplement 1):180. 87. Moran TH, Dailey MJ. Gut peptides: targets for antiobesity drug development? Endocrinology. 2009;150:2526–30. 88. Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005;48:838–48. 89. Ravussin E. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmaco- therapy. Obesity (Silver Spring). 2009;17:1736–43. 90. Takeda. Amylin and Takeda announce decision to advance development of Pramlintide/Metreleptin combination treatment for obesity. Accessed August 15 2010. http://www.takeda.com/ press/article_35851.html. 91. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349:941–8. 92. Boggiano MM, Chandler PC, Oswald KD, et al. PYY3-36 as an anti-obesity drug target. Obes Rev. 2005;6:307–22. 93. 7 TM Pharma. TM 30339 in gastrointestinal disorders. Accessed August 15, 2010 http://www.7tm.com/R-D/Gastrointestinal_ Disorders.aspx. 94. 7TM Pharma. Information on Obinepitide. Accessed August 15 2010. http://www.7tm.com/R-D/Metabolic_Disorders/Obine pitide.aspx. 95. Rosenthal J. Market watch: upcoming market catalysts in Q1 of 2010. Nat Rev Drug Discov. 2010;9:11. 96. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo- controlled study. Lancet. 2009;374:1606–16. 97. Novo Nordisk. Novo Nordisk is developing an oral GLP-1 to increase the convenience of GLP-1 treatment of type 2 diabetes. Accessed August 20, 2010. http://www.novonordisk.com/press/ rd_pipeline/rd_pipeline.asp?showid=19. 98. Chandra R, Liddle RA. Cholecystokinin. Curr Opin Endocrinol Diab Obes. 2007;14:63–7. 99. Jordan J, Greenway FL, Leiter LA, et al. Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther. 2008;83:281–7. Witkamp 100. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50:1714–9. 101. Egecioglu E, Jerlhag E, Salomé N, et al. Ghrelin increases intake of rewarding food in rodents. Addict Biol. 2010;15:304–11. 102. Yang J, Zhao TJ, Goldstein JL, Brown MS. Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides. Proc Natl Acad Sci USA. 2008;105:10750–5. 103. Moulin A, Demange L, Bergé G, et al. Toward potent ghrelin receptor ligands based on trisubstituted 1, 2, 4-triazole struc- ture. 2. Synthesis and pharmacological in vitro and in vivo evaluations. J Med Chem. 2007;50:5790–806. 104. Salomé N, Hansson C, Taube M, et al. On the central mechanism underlying ghrelin’s chronic pro-obesity effects in rats: new insights from studies exploiting a potent ghrelin receptor antagonist. J Neuroendocrinol. 2009;21:777–85. 105. Helmling S, Maasch C, Eulberg D, et al. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc Natl Acad Sci USA. 2004;101:13174–9. 106. Vizcarra JA, Kirby JD, Kim SK, Galyean ML. Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs. Domest Anim Endocrinol. 2007;33:176–89. 107. Kleinridders A, Könner AC, Brüning JC. CNS-targets in control of energy and glucose homeostasis. Curr Opin Pharmacol. 2009;9:794–804. 108. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature. 2006;443:289–95. 109. Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. NMCD. 2007;1-10. 110. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 2006;12:178–207. 111. Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Phar- macol Ther. 2010;87:652–62. 112. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1906–13. 113. Vivus Incorporated. VIVUS announces positive results from two phase 3 studies; Obese patients on Qnexa achieve average weight loss up to 14.7% and significant improvements in co- morbidities. Accessed August 10, 2010. http://ir.vivus.com/ releasedetail.cfm?ReleaseID=407933. 114. Gadde KM, Franciscy DM, Wagner HR, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289:1820–5. 115. Orexigen. Orexigen therapeutics announces that contrave(R) reduced depression scores and body weight in overweight and obese patients with major depression. Accessed August 15, 2010. http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-news Article&ID=1441841&highlight=. 116. Garfield AS, Heisler LK. Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol (Lond). 2009;587:49–60. 117. Vickers SP, Easton N, Webster LJ, et al. Oral administration of the 5-HT2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology (Berl). 2003;167:274–80. 118. Vickers SP, Dourish CT, Kennett GA. Evidence that hypopha- gia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology. 2001;41:200–9.